Gilberto Lopes

Medical Oncologist

Тhoracic oncology

The Sylvester Comprehensive Cancer Center at the University of Miami

Location USA, Miami

Linkedin

X

Dr. Gilberto Lopes is a Medical Oncologist and researcher specializing in new anticancer drug development, lung cancer, and global oncology. He is currently Professor of Clinical Medicine, Chief of the Division of Medical Oncology, and Associate Director and Medical Director for International Affairs at the Sylvester Comprehensive Cancer Center, University of Miami. His work focuses on clinical trial leadership, cancer control, health policy, health economics, and improving access to cancer medications in underserved settings; he is notably recognized as the principal investigator of KEYNOTE-042, a landmark trial that contributed to FDA approval of pembrolizumab in lung cancer.

Current Position

  • Professor of Clinical Medicine, University of Miami Miller School of Medicine
  • Chief, Division of Medical Oncology, University of Miami
  • Associate Director for the Cancer Center and Medical Director for International Affairs, Sylvester Comprehensive Cancer Center, University of Miami
  • Chair, ATOM Coalition
  • Editor-in-Chief Emeritus, JCO Global Oncology
  • Board Member, Union for International Cancer Control (UICC)

Education

  • MBA, Master of Business Administration, University of Bradford, UK (with classes in Singapore) (2009)
  • Other coursework, Lee Kwan Yew School of Public Policy, National University of Singapore, Singapore (2008)
  • ECFMG Certification, Educational Commission for Foreign Medical Graduates (1999)
  • MD, Medical Doctor, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil (1997)

Professional Experience

  • Fellowship in Hematology/Oncology, Sylvester Comprehensive Cancer Center, Jackson Memorial Hospital, University of Miami, Miami, FL (2006)
  • Chief Medical Resident and Clinical Instructor, Miami Veterans Affairs Medical Center, Jackson Memorial Hospital, University of Miami, Miami, FL (2003)
  • Internship and Residency in Internal Medicine, Jackson Memorial Hospital, University of Miami, Miami, FL (2002)
  • Residency in Internal Medicine, Hospital de Clínicas de Porto Alegre, RS, Brazil (1999)
  • Task Force Member, Influenza A (H1N1-2009) Task Force, Tan Tock Seng Hospital (2009)
  • Task Force Member, Influenza A (H1N1-2009) Task Force, Johns Hopkins Singapore International Medical Centre (2009)
  • Board of Directors, Medical Executive Board, Johns Hopkins Singapore International Medical Centre (2006)
  • Committee Member, Clinical Quality Committee, Miami Veterans Affairs Medical Center (2002)

Research Activity

  • Principal Investigator of KEYNOTE-042, a pivotal clinical trial demonstrating the efficacy of pembrolizumab monotherapy in locally advanced or metastatic non-small cell lung cancer (NSCLC), which contributed to FDA approval of pembrolizumab.
  • Leader of hundreds of clinical trials focused on new anticancer drug development, including chemotherapy, targeted therapies, and immunotherapy.
  • Research in cancer control, health policy, health economics, and access to cancer medications in underserved and low-resource settings.
  • Active research in lung cancer, neuroendocrine neoplasms, and drug development across global oncology contexts.

Academic Impact

  • Author of more than 270 peer-reviewed scientific publications.
  • Principal investigator of KEYNOTE-042, contributing to a landmark FDA approval in lung cancer immunotherapy.
  • Reviewer/Referee, NCCN Resource-Stratified Guidelines for Breast Cancer and Non-Small Cell Lung Cancer (2016).
  • Editorial contributor, JCO Global Oncology (from 2017); Editor-in-Chief Emeritus.
  • Teaching interests spanning oncology, health policy, health economics, and drug development.

Memberships / Honors / Awards

  • Board of Directors, Union for International Cancer Control (UICC) (2021)
  • Editor’s Poster Choice Award, The Lancet Oncology
  • Singapore Clinician-Investigator Award (Silver), Singapore Health and Biomedical Congress
  • Singapore Young Investigator Award (Gold), Singapore Health and Biomedical Congress
  • Doctor Award (Bronze), National Health Care Group
  • Best Poster Award, Asia Lung Cancer Forum
  • Fellow of the Year, Division of Hematology/Oncology, Sylvester Cancer Center, University of Miami Miller School of Medicine
  • Second Place, 2005 Joint Florida Cancer Center Conferences, Fellows Category
  • Young Investigator Symposium Presenter, ECOG
  • Second Place, 2005 Annual Zubrod Cancer Research Competition, University of Miami
  • Certificate of Appreciation, Miami Veterans Affairs Medical Center
  • Reviewer, South Asian Journal of Cancer (2013)
  • JAHCO Review Committee Member, Johns Hopkins Singapore International Medical Centre (2007)

Areas of Specialization

  • Lung cancer (NSCLC, SCLC) and thoracic oncology
  • New anticancer drug development and clinical trial leadership
  • Cancer immunotherapy, including PD-(L)1 inhibitors and bispecific agents
  • Neuroendocrine neoplasms and tumors
  • Global oncology and international cancer policy
  • Health economics and access to cancer medications in underserved settings
  • Cancer control and survivorship

Licensures and Certifications

  • American Board of Internal Medicine – Medical Oncology
  • American Board of Internal Medicine – Internal Medicine
  • Board Eligible in Hematology
  • Medical Oncology and Internal Medicine, Republic of Singapore
  • Medical Oncology, Brazil
  • Medical Licenses: Florida (USA), Rio de Janeiro (Brazil), São Paulo (Brazil), Rio Grande do Sul (Brazil), Republic of Singapore

Publications

Dr. Gilberto Lopes has authored more than 270 peer-reviewed scientific publications. Selected recent publications include:

LB-B002: A phase 1 trial of the oncolytic virus SVV-001 with Nivolumab and Ipilimumab in patients with high grade Neuroendocrine Neoplasms. Cancer Immunology Research. 2026.
Multiomic characterization of small cell lung cancer: Real-world insights into therapeutic opportunities. Cancer. 2026.
Pembrolizumab Monotherapy for Locally Advanced or Metastatic NSCLC: 10-Year Outcomes From Clinical Trials. Lung Cancer (Amsterdam). 2026.
A phase 1 trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors. Journal of Clinical Oncology. 2026.
A systematic literature review and meta-analysis on the efficacy and safety of PD-(L)1 inhibitors for first- and second-line treatment of locally advanced or metastatic NSCLC in Asian and non-Asian patients. Translational Lung Cancer Research. 2025.
Pembrolizumab monotherapy for locally advanced or metastatic NSCLC: 10-year outcomes from clinical trials. Annals of Oncology. 2025.
Reduction of solid tumors by senescent cell immunization. Journal of Translational Medicine. 2025.
A phase 1 trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with high grade neuroendocrine neoplasms. Journal for Immunotherapy of Cancer. 2025.
Premature Deaths and Life-Years Lost From Lack of Amivantamab in Brazil’s Unified Health System. JCO Global Oncology. 2025.
Dethroning of Neuroendocrine Tumor as an Orphan Disease: US Incidence, Prevalence, and Survival in the 21st Century. Cancers. 2025.
Long-Term Control of Leptomeningeal Disease in NSCLC With EGFR Mutations: A Case Series. Journal of Thoracic Oncology. 2025.
Multi-Institutional Real-World Experience of Early Tarlatamab-Related Toxicities for Extensive Stage Small Cell Lung Cancer. Journal of Thoracic Oncology. 2025.
Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025–2035 (Goal 9). Breast (Edinburgh). 2025.
Improving Lung Cancer Outcomes Through Policy: A Global Perspective on Risk Reduction, Early Detection, Care and Survivorship. Journal of Thoracic Oncology. 2025.
Emerging Disparities in Lung Cancer Burden in the Americas: A GLOBOCAN-Based Projection to 2050. Journal of Thoracic Oncology. 2025.
PD-(L)1 Inhibitors for Treatment of Locally Advanced or Metastatic NSCLC in Asian and Non-Asian Patients: A Meta-Analysis. Journal of Thoracic Oncology. 2025.
Efficacy and Safety of Pralsetinib in Patients With Advanced RET Fusion-Positive NSCLC: Phase 1/2 ARROW Study Final Data. Journal of Thoracic Oncology. 2025.
Global Trends in Asbestos-Related Mesothelioma Mortality From 1990 to 2021. Journal of Thoracic Oncology. 2025.
A phase I trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors. Annals of Oncology. 2025.
Low versus standard-dose anti-PD1 immunotherapy for NSCLC: A Kaplan-Meier reconstructed individual-patient data meta-analysis. Annals of Oncology. 2025.
Cost of adverse event management in first-line EGFR-mutated advanced NSCLC treated with osimertinib + platinum-pemetrexed vs amivantamab + lazertinib. Annals of Oncology. 2025.
10-year outcomes from clinical trials of pembrolizumab monotherapy for locally advanced or metastatic NSCLC. Annals of Oncology. 2025.
Phase I global study of Iza-Bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate, in patients with metastatic or unresectable NSCLC and other solid tumors. Annals of Oncology. 2025.
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma. Nature Communications. 2025.
Economic Benefits of Sponsored Clinical Trials in Cancer for the Colombian Healthcare System: A Real-World Evidence Approach. Cancer Medicine. 2025.
Evolving strategies in the management of non-small cell lung cancer brain metastases: insights from the C-Brain trial. Chinese Clinical Oncology. 2025.
International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings. JCO Oncology Practice. 2025.
Advancing evidence-based NSCLC testing and treatment across academic and community-based settings. Journal of Clinical Oncology. 2025.
Chitinase 3-like-1 (CHI3L1): A potential prognostic biomarker for immunotherapy in NSCLC. Journal of Clinical Oncology. 2025.
Clinical outcomes of a prospective multicenter study evaluating a combined ctDNA and ctRNA liquid biopsy assay in metastatic NSCLC. Journal of Clinical Oncology. 2025.
Disparities in exercise referral practices and barriers among oncologists in public and private institutions in Latin America. Journal of Clinical Oncology. 2025.
Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive NSCLC: Final data from the ARROW study. Journal of Clinical Oncology. 2025.
Escalating impact of alcohol-related cancer mortality in the US: A call for action. Journal of Clinical Oncology. 2025.
Neladalkib (NVL-655), a highly selective ALK inhibitor, compared to alectinib in first-line treatment of ALK-positive advanced NSCLC: The phase 3 ALKAZAR study. Journal of Clinical Oncology. 2025.
NVL-330, a selective HER2 tyrosine kinase inhibitor, in patients with advanced or metastatic HER2-altered NSCLC: The phase 1 HEROEX-1 study. Journal of Clinical Oncology. 2025.
Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic NSCLC (LIQUIK). JCO Precision Oncology. 2025.
PYNNACLE phase 2 clinical trial of rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. Journal of Clinical Oncology. 2025.
Women’s breast cancer mortality trends: The impact of lifestyle factors from the 2021 Global Burden of Disease study. Journal of Clinical Oncology. 2025.
Preventing Infusion-Related Reactions With Intravenous Amivantamab: Results From SKIPPirr, a Phase 2 Study. Journal of Thoracic Oncology. 2025.
Psychosocial interventions to improve quality of life in Hispanic cancer survivors: a meta-analysis. Annals of Behavioral Medicine. 2025.
Evolving trends in lung cancer risk factors in the ten most populous countries: an analysis from the 2019 Global Burden of Disease Study. EClinicalMedicine. 2025.
Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy. Frontiers in Immunology. 2025.
Safety and Tolerability of Letetresgene Autoleucel (Lete-cel): Pilot Studies in Patients With Advanced NSCLC. Clinical Cancer Research. 2024.
Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice. JCO Oncology Practice. 2024.
Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy. Cancer Research Communications. 2024.
Racial/ethnic disparities in curative-intent treatment for early-stage NSCLC among heterogeneous Black populations. Cancer Medicine. 2024.
Intra-Ethnic and Geographic Disparities in Stage at Diagnosis for Non-Small Cell Lung Cancer. JNCI: Journal of the National Cancer Institute. 2024.
ASCO Global Guidelines: Methods and Opportunities. JCO Global Oncology. 2024.
Envisioning Academic Global Oncologists: Proposed Competencies for Global Oncology Training From ASCO. JCO Global Oncology. 2024.
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. Lung Cancer (Auckland). 2024.
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant NSCLC. JCO Precision Oncology. 2024.
Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV. JAMA Network Open. 2023.
Predicting response to immunotherapy in non-small cell lung cancer: from bench to bedside. Frontiers in Oncology. 2023.
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A CCC19 cohort study. eLife. 2023.

All information is sourced from publicly available materials.